184 related articles for article (PubMed ID: 15746055)
1. T cell-dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease.
Suzuki H; Graziano DF; McKolanis J; Finn OJ
Clin Cancer Res; 2005 Feb; 11(4):1521-6. PubMed ID: 15746055
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of anticyclin B1 serum antibody as a diagnostic and prognostic biomarker for lung cancer.
Egloff AM; Weissfeld J; Land SR; Finn OJ
Ann N Y Acad Sci; 2005 Dec; 1062():29-40. PubMed ID: 16461786
[TBL] [Abstract][Full Text] [Related]
3. CD8 T-cell responses against cyclin B1 in breast cancer patients with tumors overexpressing p53.
Sørensen RB; Andersen RS; Svane IM; Engell-Noerregaard L; Hadrup SR; Balslev E; Andersen MH; thor Straten P
Clin Cancer Res; 2009 Mar; 15(5):1543-9. PubMed ID: 19223507
[TBL] [Abstract][Full Text] [Related]
4. Expression and prognostic significance of cyclin B1 and cyclin A in non-small cell lung cancer.
Cooper WA; Kohonen-Corish MR; McCaughan B; Kennedy C; Sutherland RL; Lee CS
Histopathology; 2009 Jul; 55(1):28-36. PubMed ID: 19614764
[TBL] [Abstract][Full Text] [Related]
5. Antibody and T-cell responses specific for the androgen receptor in patients with prostate cancer.
Olson BM; McNeel DG
Prostate; 2007 Dec; 67(16):1729-39. PubMed ID: 17879963
[TBL] [Abstract][Full Text] [Related]
6. Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies.
Looi K; Megliorino R; Shi FD; Peng XX; Chen Y; Zhang JY
Oncol Rep; 2006 Nov; 16(5):1105-10. PubMed ID: 17016600
[TBL] [Abstract][Full Text] [Related]
7. Expression and immunogenicity of a tumor-associated antigen, 90K/Mac-2 binding protein, in lung carcinoma.
Ozaki Y; Kontani K; Hanaoka J; Chano T; Teramoto K; Tezuka N; Sawai S; Fujino S; Yoshiki T; Okabe H; Ohkubo I
Cancer; 2002 Nov; 95(9):1954-62. PubMed ID: 12404290
[TBL] [Abstract][Full Text] [Related]
8. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients.
Schmielau J; Finn OJ
Cancer Res; 2001 Jun; 61(12):4756-60. PubMed ID: 11406548
[TBL] [Abstract][Full Text] [Related]
9. Human tankyrases are aberrantly expressed in colon tumors and contain multiple epitopes that induce humoral and cellular immune responses in cancer patients.
Shebzukhov YV; Lavrik IN; Karbach J; Khlgatian SV; Koroleva EP; Belousov PV; Kashkin KN; Knuth A; Jager E; Chi NW; Kuprash DV; Nedospasov SA
Cancer Immunol Immunother; 2008 Jun; 57(6):871-81. PubMed ID: 18026951
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of cyclin B1 protein expression in colorectal cancer.
Grabsch H; Lickvers K; Hansen O; Takeno S; Willers R; Stock W; Gabbert HE; Mueller W
Am J Clin Pathol; 2004 Oct; 122(4):511-6. PubMed ID: 15487447
[TBL] [Abstract][Full Text] [Related]
11. Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer.
Zhang H; Stephens LC; Kumar R
Clin Cancer Res; 2006 Mar; 12(5):1479-86. PubMed ID: 16533771
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of TNFalpha AutoVaccIne in patients with metastatic cancer.
Waterston AM; Gumbrell L; Bratt T; Waller S; Gustav-Aspland J; L'hermenier C; Bellenger K; Campbell M; Powles T; Highley M; Bower M; Mouritsen S; Feldmann M; Coombes RC
Cancer Immunol Immunother; 2005 Sep; 54(9):848-57. PubMed ID: 15754205
[TBL] [Abstract][Full Text] [Related]
13. The specific immune response to tumor antigen CP1 and its correlation with improved survival in colon cancer patients.
Liu FF; Dong XY; Pang XW; Xing Q; Wang HC; Zhang HG; Li Y; Yin YH; Fant M; Ye YJ; Shen DH; Zhang Y; Wang S; Chen WF
Gastroenterology; 2008 Apr; 134(4):998-1006. PubMed ID: 18395081
[TBL] [Abstract][Full Text] [Related]
14. Cyclin B1 is commonly expressed in the cytoplasm of primary human acute myelogenous leukemia cells and serves as a leukemia-associated antigen associated with autoantibody response in a subset of patients.
Ersvaer E; Zhang JY; McCormack E; Olsnes A; Anensen N; Tan EM; Gjertsen BT; Bruserud O
Eur J Haematol; 2007 Sep; 79(3):210-25. PubMed ID: 17655707
[TBL] [Abstract][Full Text] [Related]
15. Nuclear cyclin B1 is overexpressed in low-malignant-potential ovarian tumors but not in epithelial ovarian cancer.
Zheng H; Hu W; Deavers MT; Shen DY; Fu S; Li YF; Kavanagh JJ
Am J Obstet Gynecol; 2009 Oct; 201(4):367.e1-6. PubMed ID: 19608149
[TBL] [Abstract][Full Text] [Related]
16. Increased levels of a 21-kDa protein in the circulation of tumor-bearing patients.
Shalitin C; Epelbaum R; Moskovitz B; Segal R; Valansi C; Werner M; Livne PM
Cancer Detect Prev; 1994; 18(5):357-65. PubMed ID: 7812982
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral cytokines and tumor cell biology determine spontaneous breast cancer-specific immune responses and their correlation to prognosis.
Domschke C; Schuetz F; Ge Y; Seibel T; Falk C; Brors B; Vlodavsky I; Sommerfeldt N; Sinn HP; Kühnle MC; Schneeweiss A; Scharf A; Sohn C; Schirrmacher V; Moldenhauer G; Momburg F; Beckhove P
Cancer Res; 2009 Nov; 69(21):8420-8. PubMed ID: 19843863
[TBL] [Abstract][Full Text] [Related]
18. Immunoglobulin E antibodies from pancreatic cancer patients mediate antibody-dependent cell-mediated cytotoxicity against pancreatic cancer cells.
Fu SL; Pierre J; Smith-Norowitz TA; Hagler M; Bowne W; Pincus MR; Mueller CM; Zenilman ME; Bluth MH
Clin Exp Immunol; 2008 Sep; 153(3):401-9. PubMed ID: 18803764
[TBL] [Abstract][Full Text] [Related]
19. Cyclin B1 and other cyclins as tumor antigens in immunosurveillance and immunotherapy of cancer.
Egloff AM; Vella LA; Finn OJ
Cancer Res; 2006 Jan; 66(1):6-9. PubMed ID: 16397206
[TBL] [Abstract][Full Text] [Related]
20. Premalignant lesions as targets for cancer vaccines.
Finn OJ
J Exp Med; 2003 Dec; 198(11):1623-6. PubMed ID: 14638849
[No Abstract] [Full Text] [Related]
[Next] [New Search]
